Literature DB >> 1761076

Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

G Muralidharan1, E M Hawes, G McKay, E D Korchinski, K K Midha.   

Abstract

Healthy male volunteers (n = 13) took a single oral dose of 60.3 mg of methoxyphenamine HCl with and without prior administration of either quinidine (250 mg as bisulphate salt) or its diastereomer quinine (300 mg as sulphate salt). Methoxyphenamine and its N-desmethyl, O-desmethyl and aromatic 5-hydroxy metabolites were quantified in the 0-32 h urine. The oxidative routes of methoxyphenamine metabolisms which had been previously shown to involve debrisoquine 4-hydroxylase, namely O-demethylation and 5-hydroxylation were both significantly inhibited by quinidine in the 12 extensive metabolizers. The inhibition was selective in that N-demethylation which does not involve this isozyme was not affected by quinidine. In all but one of these volunteers the methoxyphenamine/O-desmethylmethoxyphenamine ratio changed such that extensive metabolizers could be classified as poor metabolizers due to quinidine pretreatment. No marked change occurred in the renal excretion of methoxyphenamine and its three metabolites either in the extensive metabolizers because of quinine pretreatment or in the poor metabolizer because of treatment with either quinidine or quinine. Thus in the extensive metabolizer phenotype it was demonstrated in one study that enzyme inhibition of quinidine was selective in terms of the metabolic pathways inhibited as well as stereoselective with respect to the inhibitor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761076     DOI: 10.1007/BF00626372

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Inhibition of desipramine 2-hydroxylation by quinidine and quinine.

Authors:  E Steiner; E Dumont; E Spina; R Dahlqvist
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

3.  Stereoselective renal tubular secretion of quinidine and quinine.

Authors:  D A Notterman; D E Drayer; L Metakis; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1986-11       Impact factor: 6.875

4.  Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans.

Authors:  S D Roy; E M Hawes; K K Midha
Journal:  J Pharm Sci       Date:  1987-06       Impact factor: 3.534

5.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.

Authors:  S D Roy; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

6.  Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine.

Authors:  A Hedman; B Angelin; A Arvidsson; R Dahlqvist; B Nilsson
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

Review 7.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

Authors:  C Funck-Brentano; J Turgeon; R L Woosley; D M Roden
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

9.  Sparteine oxidation is practically abolished in quinidine-treated patients.

Authors:  R Brinn; K Brøsen; L F Gram; T Haghfelt; S V Otton
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

10.  Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more
  5 in total

1.  Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.

Authors:  Wenjie Jessie Lu; Valentina Ferlito; Cong Xu; David Alastair Flockhart; Salvatore Caccamese
Journal:  Chirality       Date:  2011-09-22       Impact factor: 2.437

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.

Authors:  D Young; K K Midha; M J Fossler; E M Hawes; J W Hubbard; G McKay; E D Korchinski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Quinine and quinidine inhibit and reveal heterogeneity of K-Cl cotransport in low K sheep erythrocytes.

Authors:  N C Adragna; P K Lauf
Journal:  J Membr Biol       Date:  1994-11       Impact factor: 1.843

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.